Advertisement

Topics

Metabolomic analysis of serum and myocardium in compensated heart failure after myocardial infarction.

07:00 EST 4th February 2019 | BioPortfolio

Summary of "Metabolomic analysis of serum and myocardium in compensated heart failure after myocardial infarction."

To determine the metabolic adaptations to compensated heart failure using a reproducible model of myocardial infarction and an unbiased metabolic screen. To address the limitations in sample availability and model variability observed in preclinical and clinical metabolic investigations of heart failure.

Affiliation

Journal Details

This article was published in the following journal.

Name: Life sciences
ISSN: 1879-0631
Pages:

Links

DeepDyve research library

PubMed Articles [22798 Associated PubMed Articles listed on BioPortfolio]

Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK.

At present, the clinical burden of hypokalaemia and hyperkalaemia among European heart failure patients, and relationships between serum potassium and adverse clinical outcomes in this population, is ...

Empagliflozin directly improves diastolic function in human heart failure.

Empagliflozin, a clinically used oral antidiabetic drug that inhibits the sodium-dependent glucose co-transporter 2, has recently been evaluated for its cardiovascular safety. Surprisingly, empagliflo...

Iron Deficiency in Heart Failure: An Overview.

Iron deficiency is an extremely common co-morbidity in patients with heart failure, affecting up to 50% of all ambulatory patients. It is associated with reduced exercise capacity and physical well-be...

Mesenchymal stem cell therapy for heart failure: a meta-analysis.

Mesenchymal stem cell (MSC) treatment has emerged as an important adjunct therapy for heart failure. However, the use of MSC to treat heart failure has not been well established. We conducted a syste...

Myocardial relaxation in human heart failure: Why sarcomere kinetics should be center-stage.

Myocardial relaxation is critical for the heart to allow for adequate filling of the ventricles prior to the next contraction. In human heart failure, impairment of myocardial relaxation is a major pr...

Clinical Trials [10833 Associated Clinical Trials listed on BioPortfolio]

Autologous Mesenchymal Stromal Cell Therapy in Heart Failure

It is a single centre, randomised controlled study of the effect of NOGA-guided direct intramyocardial injection of mesenchymal stromal cells on the development of new myocardium and blood...

Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure

The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional an...

Effect of Aldosterone on Energy Starvation in Heart Failure

We plan to study the concept of "energy starvation" in heart failure by evaluation of patients with nonischemic dilated cardiomyopathy (heart failure with reduced heart pump function due t...

Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI in Heart Failure

The investigators hypothesised that novel MRI metrics derived from myocardium post-gadolinium T1 mapping analysis will improve the current knowledge about the role interstitial fibrosis an...

Novel INXN-4001 in Heart Failure - INXN-4001 Phase 1 in Heart Failure

To evaluate the safety of INXN-4001 infusion into the myocardium of outpatient LVAD recipients as assessed by incidence of all study intervention - related adverse events occurring up to 6...

Medical and Biotech [MESH] Definitions

A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Rare congenital cardiomyopathies characterized by the lack of left ventricular myocardium compaction. The noncompaction results in numerous prominent trabeculations and a loose myocardial meshwork (spongy myocardium) in the LEFT VENTRICLE. Heterogeneous clinical features include diminished systolic function sometimes associated with left ventricular dilation, that presents either neonatally or progressively. Often, the RIGHT VENTRICLE is also affected. CONGESTIVE HEART FAILURE; PULMONARY EMBOLISM; and ventricular ARRHYTHMIA are commonly seen.

Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.

Heart failure caused by abnormal myocardial relaxation during DIASTOLE leading to defective cardiac filling.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article